GEN Exclusives

More »

The Lists

More »
Oct 2, 2012

Top 20 Molecular Millionaires

Which biopharma company leaders are raking in the most in shares?

Top 20 Molecular Millionaires

Among the millionaires who’ve made their fortunes by investing in biotech, these 20 top the list. [AlienForce - Fotolia.com]

  • Molecules often not only lead to novel drugs but they also can make researchers and biotech company officials new millionaires—sometimes extravagantly wealthy ones. If you have any doubts, take a look at our list of the top 20 molecular millionaires in the biotech and pharma businesses. Their biopharma stock holdings can rival those of other major industries, which is probably something not many people saw in the cards in 1973 when Cohen and Boyer carried out the first experiment in genetic engineering.

    Below are leaders of public biopharma companies listed by the value of their common shares as of the day they were tallied and recorded in filings, following the number of common shares they held on a given day, and that day’s closing share price.

  • #20. Christopher Viehbacher

    CEO, Sanofi

    Total value of common shares owned: $6,995,308

    95,442 common shares owned as of Dec. 31, 2011

    Closing price: $73.29 as of Dec. 30, 2011 (no trading on Dec. 31) [converted on Sept. 27, 2012 from €56.75]

  • #19. Kenneth C. Frazier

    Chairman, President, and CEO, Merck & Co.

    Total value of common shares owned: $7,372,084

    195,546 common shares owned as of Dec. 31, 2011

    Closing price: $37.70 as of Dec. 30, 2011 (no trading on Dec. 31)

  • #18. Matthew W. Emmens

    Chairman, President, & CEO, Vertex Pharmaceuticals

    Total value of common shares owned: $8,811,065

    211,601 common shares owned as of March 19, 2012

    Closing price: $41.64

  • #17. Lamberto Andreotti

    CEO, Bristol-Myers Squibb

    Total value of common shares owned: $8,830,034.40

    272,112 common shares owned as of Feb. 28, 2012

    Closing price: $32.45

  • #16. Sir Andrew Witty

    CEO, GlaxoSmithKline

    Total value of common shares owned: $10,013,823.13

    434,924 common shares owned as of March 9, 2012

    Closing price: $23.01 [Converted on Sept. 27, 2012, from 1,418.50 pence = £14.1850 or $23.0125]

  • #15. Ian C. Read

    Chairman and CEO, Pfizer

    Total value of common shares owned: $10,414,994.80

    486,682 common shares owned as of Jan. 31, 2012

    Closing price: $21.40

  • #14. David Brennan1

    CEO, AstraZeneca

    Total value of common shares owned: $11,891,033.16

    246,174 common shares owned as of Dec. 31, 2011

    Closing price: $48.31 as of Dec. 30, 2011 (no trading on Dec. 31) [Converted Sept. 27, 2012, from 2,975.00 pence = £29.75 or $48.3113]

  • #13. Robert L. Parkinson, Jr.

    Chairman and CEO, Baxter

    Total value of common shares owned: $21,722,916.60

    391,545 common shares owned as of Jan. 31, 2012

    Closing price: $55.48

  • #12. Brian Anthony McNamee

    CEO and Managing Director, CSL

    Total value of common shares owned: $28,861,189.70

    835,669 common shares owned as of June 30, 2011

    Closing price: $34.54 [Converted on Sept. 27, 2012, from A$33.06]

  • #11. Howard Solomon

    Chairman, President, and CEO, Forest Laboratories

    Total value of common shares owned: $31,058,871.48

    929,628 common shares owned as of June 25, 2012

    Closing price: $33.41


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Eyes on the Science Prizes

The proliferation of big-money science prizes might be seen as cheering or worrisome. Where do you stand?